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ABSTRACT 
OBJECTIVE: To assess the value of extended volume irradiation with anastomotic coverage in high 
risk resected esophageal cancer patients. 
METHOD: A retrospective study was undertaken at LRCC from 1989-1999 for high risk resected 
esophageal cancer patients.  Adjuvant treatments consisted of 4 cycles of chemotherapy 
(epirubicin/fluorouracil/cisplatin or cisplatin/fluorouracil), and local regional irradiation with or without 
coverage of the anastomotic site.  Radiation dose ranged from 45-60Gy at 1.8-2.0 Gy/fraction given with 
initial anterior-posterior/posterior-anterior arrangement with either extended (with anastomotic coverage) 
or small (without anastomotic coverage) field followed by oblique fields for boost. 
RESULT: One hundred eighty-eight charts were reviewed.  Seventy-two patients were eligible for 
post-resection chemoradiation therapy.  Three patients had disease progression prior to therapy, and 69 
patients were analyzed.  There were 81% T3N1 and 13% T2N1.  Thirty-four patients had margin 
involvements (radial 53%; proximal/distal 32%), 65% were adenocarcinoma and 33% were squamous 
carcinoma.  Median followup was 23.6 months (3.4 - 78.4 months).  Two year survival was 50%; 5yr 24%.  
Relapse rate was 62.3% and median time to relapse was 20 months.  Recurrence locally to anastomosis 
or adjacent to anastomosis was 9/43(20.9%) with small field and 2/26(7.7%) with extended field.  Of 31 
patients with relapse outside anastomosis, 14/20(70%) relapsed locoregional/distal when treated with 
small field and 3/11(27%) relapsed locoregional/distal when treated with extended field (p=0.02).  There 
was no excess treatment interruption or chronic gastrointestinal toxicity with extended field irradiation. 
CONCLUSION: There is significant decrease in locoregional/distal relapse with use of extended 
field in high risk resected esophageal cancer patients. 
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Introduction 
• surgery has been the standard treatment for localized esophageal cancer (1) 
 
• anastomotic recurrence of disease after transthoracic esophagectomy can occur, particularly 
with histologically involved surgical margins (2) 
 
• frequency of locoregional recurrence is related to the length of resection margin (3), lymph 
node involvement (4), invasion of neighbouring organs (5) and circumferential resection 
margin involvement (6) 
 
• radiation treatment planning and target volume for esophageal cancer patients is 
controversial (7).  There is no clear consensus as to what constitutes the optimal treatment 
volume and the balance between tumor control and normal tissue toxicity for high risk 
patients (close or positive microscopic margins and lymph node involvement) after 
esophagectomy 
 
• at LRCC thoracic radiation oncologists have different practice preferences on the inclusion 
of the post-surgical anastomotic site within the irradiation volume even if the pathological 
margins (proximal and distal) are not involved 
 
• the present study is to review the results of those high risk patients after esophagectomy 
treated with either small (without anastomotic coverage) or extended (with anastomotic 
coverage) field of radiation at LRCC during the period of 1989-1999 
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Patient & Methods 
• a retrospective chart review was undertaken at London Regional Cancer Centre (LRCC) 
from 1989-1999, for high risk resected esophageal cancer patients (T3 disease with nodal 
involvement, positive margin and/or with residual disease) 
• adjuvant treatments consisted of 4 cycles of chemotherapy i.e. ECF (epirubicin 50 mg/m2, 5 
FU 200 mg/m2 and cisplatin 60 mg/m2) with epirubicin omitted during the concurrent phase 
with radiation therapy or 4 cycles of cisplatin (100 mg/m2) and 5 FU (1000 mg/m2) 
• irradiation was given during the 3rd cycle of chemotherapy.  Irradiation dose ranged from 45-
60 Gy at 1.8 - 2.0 Gy/fx given with initial anterior-posterior/posterior-anterior arrangement 
with either extended (with anastomotic coverage - field size range 22 x 12 cm - 28 cm x 12 - 
median 24 x 12 cm) or small (without anastomotic coverage - field size range 12 x 10 cm - 
22 x 12 cm - median 19 x 12 cm) field followed by oblique fields for boost 
• resection margins were covered within the radiation portal if it was close or involved 
regardless of whether small or extended field was used 
• megavoltage machine with energy > 6 MV were used 
• statistic was analyzed with chi-square and Log Rank 
• treatment toxicity including chemo/radiation delay, chemotherapy dose reduction  GI 
symptoms such as esophagitis, diarrhea, bowel obstruction, tracheo esophageal fistula etc. 
were analyzed 
5 
Results 
 
Total:  188 patient charts reviewed 
  72 patients referred to LRCC with high risk features for adjuvant chemoradiation  
therapy 
  3 patients with disease progression while on treatment 
  69 patients analyzed 
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Results 
 
Patient Characteristics: 
Age < 65 yo  41 (59%) range  35-82 yo. median 60 yo 
 > 65 yo.  28 (41%) 
Sex  male  62 (90%) 
  Female 7 (10%) 
Pathological  
 Stage  T2N1  9 (13%) 
   T3N1  55 (81%) 
   T4N0  2 (3%) 
   T4N1  2 (3%) 
Surgery  Transhiatal 59 (86%) 
   Transthoracic 10 (14%) 
Pathology 
  Squamous  23 (33%) 
  Adenocarcinoma 45 (65%) 
  Other     1 (1%) 
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Results 
Margin features 
34 patients with margin involvement 
  proximal/distal margins  11/69  (15%) 
  close/involvement 
  radial margins    18/69  (26%) 
  close/involvement 
  both     5/69  (7%) 
Patient With Extended Field 
Margin Involvement  20/26  (77%) 
9/26  (35%)  radical margin 
7/26  (27%)  proxi/distal margin 
4/26  (15%)  both 
 
Patient With Small Field 
Margin Involvement 14/43  (33%) 
9/43 (21%) radical margin 
4/43  (10%)   proxi/distal margin 
1/43  (2%)   both 
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Results 
Treatment 
 Chemotherapy 
  Cisp + 5 FU  = 47 (68%) 
  ECF   = 20 (29%) 
  Other   = 2 (3%) 
 Radiation Therapy 
Extended Volume (covering anastomosis) 
   26/69  patients  (37.6%) 
  Small Volume (without covering anastomosis) 
   43/69  patients  (62.4%) 
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Results 
Follow-up: 
 3.4 - 78.4 months   median 23.6 months 
Survival: 
 Overall 2 years 50% 
 5 years  24% 
Survival curve: 
Overall Survival 
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Results 
Relapse: 
 Rate  43/69  (62.3%) 
 Median time relapse  19.9 months 
Pattern: 
 Local Regional  9/43  (20%) 
 Local Regional Distal  17/43  (40%) 
 Distal Only   17/43  (40%) 
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Results 
Relapse sites       Number of Relapse 
neck nodes/mass       9 
bone         9 
abdominal mass       7 
liver         6 
lung         6 
brain         4 
skin         2 
stomach        2 
adrenal        2 
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Results 
Anastomosis relapse: 
 of 9 patients with local regional relapse (all not covered anastomosis site) 
  5 recurred to anastomotic site only 
  4 recurred adjacent to anastomotic site 
  ∴ anastomotic recurrence rate (without coverage by XRT) 9/43 (20.9%) 
∴ anastomotic  recurrence rate (with coverage by XRT) 2/26 (7.7%) 
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Results 
Relapse outside anastomosis    31 patients 
Treatment volume Patient number Local regional distal 
relapse 
Distal relapse only 
Small field 20 14 6 
Extended field 11 3 8 
 
p = 0.02 chi square 
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Results 
Effects of Various Factors on Relapse-Free Interval 
 
 
Factor Log Rank P-Value 
Margin-negative vs. positive 0.66 
Resection margin-small field 
vs. extended field 
0.86 
Type of surgery - transhiatal 
vs. transthoracic 
0.74 
ECF Chemo regimen- yes vs. 
no 
0.22 
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Results 
Complications: 
• XRT interruption    small field vs extended field  p  =  0.26 chi2 
 
• Chemotherapy delays   small field vs. extended field  p  =  0.09 chi2 
 
• Chemotherapy dose reduction   small field vs. extended field  p  =  1.0 chi2 
 
• Late toxicity (L’Hermites,    small field vs. extended field   p  =  0.70 chi2 
      trachoesophageal fistula, bowel  
      obstruction, Liver/Kidney damage,  
      peripheral neuropathy, weight loss,  
      chronic diarrhea, etc)  
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Summary and Conclusion 
 
1. In our patient population with high risk post-resection relapse rate was 62.3%. 
 
2. Anastomosis recurrence of 20% if it is not covered with XRT portal. 
 
3. There is significant decrease in locoregional/distal relapse with use of extended field in 
high risk resected esophageal cancer patients. 
 
4. There is no increase in late toxicity, XRT interruption, and chemotherapy delay when 
extended irradiation field is used. 
 
5. Ongoing phase I/II trial at LRCC to examine the feasibility of extended target volume for 
radiation therapy of resected high risk esophageal cancer patients. 
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